Drug Profile

Research programme: small molecule therapeutics - Alion Pharmaceuticals

Latest Information Update: 09 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alion Pharmaceuticals
Class Antidementias; Small molecules
Mechanism of Action Ion channel modulators; Protein interaction domain and motif modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

09 Feb 2024 Small molecule therapeutics are still in research trials for Alzheimer disease in USA (Alion Pharmaceuticals pipeline, February 2024)
28 May 2022 No recent reports of development identified for research development in Alzheimer's-disease in USA
02 Apr 2018 Research programme: small molecule therapeutics - Alion Pharmaceuticals is available for licensing as of 02 Apr 2018. https://www.alionpharmaceuticals.com

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com